Drug industry should watch proposed parallel reviews by FDA, CMS

02/19/2008 | RPM Report (free registration), The

FDA and CMS officials say a parallel review process could speed marketing approval and reimbursement, but industry experts say the program could delay products from reaching the market and add to cost and data requirements. Biotech and pharma companies may not feel an immediate impact because the program is voluntary, affects mostly device firms and is years from implementation, but the industry still should monitor signs of closer cooperation between the agencies, according to this RPM Report analysis.

View Full Article in:

RPM Report (free registration), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX